{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:23Z","timestamp":1790890943765,"version":"4.1.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03564-1","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:37:55Z","timestamp":1746855475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["CAR-T cell therapy for juvenile-onset autoimmune diseases: a promising future?"],"prefix":"10.1186","volume":"27","author":[{"given":"Maurine","family":"Jouret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Viel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Benezech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9rome","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Scherlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the C3I consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetane","family":"Nocturne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Terrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Bigenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Richez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divi","family":"Cornec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Sibilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahir","family":"Amoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Donnadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bousso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Decroocq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Forcade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jorgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"3564_CR1","doi-asserted-by":"publisher","first-page":"108274","DOI":"10.1016\/j.clim.2019.108274","volume":"209","author":"EMD Smith","year":"2019","unstructured":"Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;209:108274. https:\/\/doi.org\/10.1016\/j.clim.2019.108274.","journal-title":"Clin Immunol"},{"key":"3564_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","volume":"19","author":"C Papadopoulou","year":"2023","unstructured":"Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. Nat Rev Rheumatol. 2023;19:343\u201362. https:\/\/doi.org\/10.1038\/s41584-023-00967-9.","journal-title":"Nat Rev Rheumatol"},{"key":"3564_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/art.20412","volume":"51","author":"N Ruperto","year":"2004","unstructured":"Ruperto N, Buratti S, Duarte-Salazar C, Pistorio A, Reiff A, Bernstein B, et al. Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. Arthritis Care Res. 2004;51:458\u201364. https:\/\/doi.org\/10.1002\/art.20412.","journal-title":"Arthritis Care Res"},{"key":"3564_CR4","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1093\/rheumatology\/keab805","volume":"61","author":"BN Witczak","year":"2022","unstructured":"Witczak BN, Bollerslev J, Godang K, Schwartz T, Flat\u00f8 B, Molberg \u00d8, et al. Body composition in long-standing juvenile dermatomyositis: associations with disease activity, muscle strength and cardiometabolic measures. Rheumatology. 2022;61:2959\u201368. https:\/\/doi.org\/10.1093\/rheumatology\/keab805.","journal-title":"Rheumatology"},{"key":"3564_CR5","doi-asserted-by":"publisher","first-page":"109028","DOI":"10.1016\/j.clim.2022.109028","volume":"239","author":"EMD Smith","year":"2022","unstructured":"Smith EMD, Egbivwie N, Jorgensen AL, Ciurtin C, Al-Abadi E, Armon K, et al. Real world treatment of juvenile-onset systemic lupus erythematosus: Data from the UK JSLE cohort study. Clin Immunol. 2022;239:109028. https:\/\/doi.org\/10.1016\/j.clim.2022.109028.","journal-title":"Clin Immunol"},{"key":"3564_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.clim.2013.08.009","volume":"149","author":"P Costa-Reis","year":"2013","unstructured":"Costa-Reis P, Nativ S, Isgro J, Rodrigues T, Yildirim-Toruner C, Starr A, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol. 2013;149:442\u20139. https:\/\/doi.org\/10.1016\/j.clim.2013.08.009.","journal-title":"Clin Immunol"},{"key":"3564_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.23290","volume":"70","author":"AM Knight","year":"2018","unstructured":"Knight AM, Trupin L, Katz P, Yelin E, Lawson EF. Depression risk in young adults with juvenile- and adult-onset lupus: twelve years of followup. Arthritis Care Res. 2018;70:475\u201380. https:\/\/doi.org\/10.1002\/acr.23290.","journal-title":"Arthritis Care Res"},{"key":"3564_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.berh.2005.11.003","volume":"20","author":"MW Beresford","year":"2006","unstructured":"Beresford MW, Davidson JE. Adolescent development and SLE. Best Pract Res Clin Rheumatol. 2006;20:353\u201368. https:\/\/doi.org\/10.1016\/j.berh.2005.11.003.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3564_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fimmu.2019.00214","volume":"10","author":"MGL Wilkinson","year":"2019","unstructured":"Wilkinson MGL, Rosser EC. B cells as a therapeutic target in paediatric rheumatic disease. Front Immunol. 2019;10:214. https:\/\/doi.org\/10.3389\/fimmu.2019.00214.","journal-title":"Front Immunol"},{"key":"3564_CR10","doi-asserted-by":"publisher","first-page":"27479","DOI":"10.1038\/srep27479","volume":"6","author":"W Li","year":"2016","unstructured":"Li W, Tian X, Lu X, Peng Q, Shu X, Yang H, et al. Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis. Sci Rep. 2016;6:27479. https:\/\/doi.org\/10.1038\/srep27479.","journal-title":"Sci Rep"},{"key":"3564_CR11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.3389\/fimmu.2018.01372","volume":"9","author":"CJM Piper","year":"2018","unstructured":"Piper CJM, Wilkinson MGL, Deakin CT, Otto GW, Dowle S, Duurland CL, et al. CD19+CD24hiCD38hi B cells are expanded in juvenile dermatomyositis and exhibit a pro-inflammatory phenotype after activation through toll-like receptor 7 and interferon-\u03b1. Front Immunol. 2018;9:1372. https:\/\/doi.org\/10.3389\/fimmu.2018.01372.","journal-title":"Front Immunol"},{"key":"3564_CR12","doi-asserted-by":"publisher","first-page":"keae163","DOI":"10.1093\/rheumatology\/keae163.034","volume":"63","author":"AEK Syntakas","year":"2024","unstructured":"Syntakas AEK, Nguyen HD, Restuadi R, Jebson BR, Alexiou V, Marshall LR, et al. OA34 Unravelling the role of B cells and interferon dysregulation in juvenile dermatomyositis. Rheumatology. 2024;63:keae163-034. https:\/\/doi.org\/10.1093\/rheumatology\/keae163.034.","journal-title":"Rheumatology"},{"key":"3564_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81:100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"key":"3564_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66:740\u20139. https:\/\/doi.org\/10.1002\/art.38270.","journal-title":"Arthritis Rheumatol"},{"key":"3564_CR15","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1002\/art.38037","volume":"65","author":"EF Mysler","year":"2013","unstructured":"Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, Phase III Study. Arthritis Rheum. 2013;65:2368\u201379. https:\/\/doi.org\/10.1002\/art.38037.","journal-title":"Arthritis Rheum"},{"key":"3564_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei HE, Schmidt S, D\u00f6rner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther. 2012;14:S1. https:\/\/doi.org\/10.1186\/ar3909.","journal-title":"Arthritis Res Ther"},{"key":"3564_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-024-06461-8","volume":"15","author":"MJ Montalvo","year":"2024","unstructured":"Montalvo MJ, Bandey IN, Rezvan A, Wu K-L, Saeedi A, Kulkarni R, et al. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death Dis. 2024;15:1\u201314. https:\/\/doi.org\/10.1038\/s41419-024-06461-8.","journal-title":"Cell Death Dis"},{"key":"3564_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"3564_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up. N Engl J Med. 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"3564_CR20","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, V\u00f6lkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology. 2024;63:e12\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kead330.","journal-title":"Rheumatology"},{"key":"3564_CR21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401:815\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(23)00023-5.","journal-title":"Lancet"},{"key":"3564_CR22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024;403:1627\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(24)00424-0.","journal-title":"Lancet"},{"key":"3564_CR23","doi-asserted-by":"publisher","unstructured":"Marasco E, Bracaglia C, Merli P, Alvarez PM, Nicolai R, Algeri M, et al. P101 Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus. Poster Present., Lupus Foundation of America; 2024, p. A113.1-A113. https:\/\/doi.org\/10.1136\/lupus-2024-el.155.","DOI":"10.1136\/lupus-2024-el.155"},{"key":"3564_CR24","doi-asserted-by":"publisher","unstructured":"Nicolai R, Merli P, Moran Alvarez P, Bracaglia C, Del Bufalo F, Marasco E, et al. Autologous CD19\u2010 targeting CAR T cells in refractory juvenile dermatomyositis. Arthritis Rheumatol 2024:art.42933. https:\/\/doi.org\/10.1002\/art.42933.","DOI":"10.1002\/art.42933"},{"key":"3564_CR25","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/rheumatology\/34.9.866","volume":"34","author":"LB Tucker","year":"1995","unstructured":"Tucker LB, Menon S, Schaller JG, Isenberg DA. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Rheumatology. 1995;34:866\u201372. https:\/\/doi.org\/10.1093\/rheumatology\/34.9.866.","journal-title":"Rheumatology"},{"key":"3564_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jpeds.2004.12.045","volume":"146","author":"B Bader-Meunier","year":"2005","unstructured":"Bader-Meunier B, Armengaud JB, Haddad E, Salomon R, Desch\u00eanes G, Kon\u00e9-Paut I, et al. Initial presentation of childhood-onset systemic lupus erythematosus: a French multicenter study. J Pediatr. 2005;146:648\u201353. https:\/\/doi.org\/10.1016\/j.jpeds.2004.12.045.","journal-title":"J Pediatr"},{"key":"3564_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A. Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep. 2021;23:1\u20135.","journal-title":"Curr Rheumatol Rep."},{"key":"3564_CR28","doi-asserted-by":"publisher","first-page":"107456","DOI":"10.1016\/j.rmed.2023.107456","volume":"220","author":"JG Palafox-Flores","year":"2023","unstructured":"Palafox-Flores JG. Systemic lupus erythematosus in pediatric patients: Pulmonary manifestations. Respir Med. 2023;220:107456.","journal-title":"Respir Med."},{"key":"3564_CR29","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10875-022-01407-1","volume":"43","author":"M Labouret","year":"2023","unstructured":"Labouret M, Costi S, Bondet V, Trebossen V, Le Roux E, Ntorkou A, et al. Juvenile neuropsychiatric systemic lupus erythematosus: identification of novel central neuroinflammation biomarkers. J Clin Immunol. 2023;43:615\u201324. https:\/\/doi.org\/10.1007\/s10875-022-01407-1.","journal-title":"J Clin Immunol"},{"key":"3564_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1177\/0961203319853621","volume":"28","author":"M Quilter","year":"2019","unstructured":"Quilter M, Hiraki L, Korczak D. Depressive and anxiety symptom prevalence in childhood-onset systemic lupus erythematosus: a systematic review. Lupus. 2019;28:878\u201387. https:\/\/doi.org\/10.1177\/0961203319853621.","journal-title":"Lupus"},{"key":"3564_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1177\/0961203316644333","volume":"25","author":"N Ambrose","year":"2016","unstructured":"Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25:1542\u201350. https:\/\/doi.org\/10.1177\/0961203316644333.","journal-title":"Lupus"},{"key":"3564_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.semarthrit.2012.05.001","volume":"42","author":"B Livingston","year":"2012","unstructured":"Livingston B, Bonner A, Pope J. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2012;42:271\u201380. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.05.001.","journal-title":"Semin Arthritis Rheum"},{"key":"3564_CR33","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1002\/art.34410","volume":"64","author":"L Watson","year":"2012","unstructured":"Watson L, Leone V, Pilkington C, Tullus K, Rangaraj S, McDonagh JE, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum. 2012;64:2356\u201365. https:\/\/doi.org\/10.1002\/art.34410.","journal-title":"Arthritis Rheum"},{"key":"3564_CR34","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/rheumatology\/ket488","volume":"53","author":"B Amaral","year":"2014","unstructured":"Amaral B, Murphy G, Ioannou Y, Isenberg DA. A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. Rheumatology. 2014;53:1130\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/ket488.","journal-title":"Rheumatology"},{"key":"3564_CR35","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.semarthrit.2016.03.009","volume":"46","author":"L Chiche","year":"2016","unstructured":"Chiche L, Jourde-Chiche N, Bader-Meunier B, Retornaz F, Malaekah S, Eb M, et al. Acute pancreatitis as a cause of mortality in pediatric systemic lupus erythematosus: results of a multiple cause-of-death analysis in France. Semin Arthritis Rheum. 2016;46:e6-7. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.03.009.","journal-title":"Semin Arthritis Rheum"},{"key":"3564_CR36","first-page":"538","volume":"27","author":"A Klein","year":"2009","unstructured":"Klein A, Cimaz R, Quartier P, Decramer S, Niaudet P, Baudouin V, et al. Causes of death in pediatric systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27:538\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"3564_CR37","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-024-01696-8","volume":"44","author":"M Tusseau","year":"2024","unstructured":"Tusseau M, Khaldi-Plassart S, Cognard J, Viel S, Khoryati L, Benezech S, et al. Mendelian causes of autoimmunity: the lupus phenotype. J Clin Immunol. 2024;44:99. https:\/\/doi.org\/10.1007\/s10875-024-01696-8.","journal-title":"J Clin Immunol"},{"key":"3564_CR38","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/S2665-9913(19)30142-0","volume":"2","author":"A Belot","year":"2020","unstructured":"Belot A, Rice GI, Omarjee SO, Rouchon Q, Smith EMD, Moreews M, et al. Contribution of rare and predicted pathogenic gene variants to childhood-onset lupus: a large, genetic panel analysis of British and French cohorts. Lancet Rheumatol. 2020;2:e99-109. https:\/\/doi.org\/10.1016\/S2665-9913(19)30142-0.","journal-title":"Lancet Rheumatol"},{"key":"3564_CR39","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/ard-2022-223328","volume":"82","author":"EMD Smith","year":"2023","unstructured":"Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al. Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus: PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis. 2023;82:788\u201398. https:\/\/doi.org\/10.1136\/ard-2022-223328.","journal-title":"Ann Rheum Dis"},{"key":"3564_CR40","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1177\/09612033221115974","volume":"31","author":"R Semo-Oz","year":"2022","unstructured":"Semo-Oz R, Wagner-Weiner L, Edens C, Zic C, One K, Saad N, et al. Adherence to medication by adolescents and young adults with childhood-onset systemic lupus erythematosus. Lupus. 2022;31:1508\u201315. https:\/\/doi.org\/10.1177\/09612033221115974.","journal-title":"Lupus"},{"key":"3564_CR41","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","volume":"76","author":"N Groot","year":"2017","unstructured":"Groot N, De Graeff N, Marks SD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76:1965\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211898.","journal-title":"Ann Rheum Dis"},{"key":"3564_CR42","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/0961203315622821","volume":"25","author":"A Fanouriakis","year":"2016","unstructured":"Fanouriakis A, Pamfil C, Sidiropoulos P, Damian L, Flestea A, Gusetu G, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016;25:627\u201336. https:\/\/doi.org\/10.1177\/0961203315622821.","journal-title":"Lupus"},{"key":"3564_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11926-014-0489-5","volume":"17","author":"ZS Ar\u0131c\u0131","year":"2015","unstructured":"Ar\u0131c\u0131 ZS, Batu ED, Ozen S. Reviewing the recommendations for lupus in children. Curr Rheumatol Rep. 2015;17:17. https:\/\/doi.org\/10.1007\/s11926-014-0489-5.","journal-title":"Curr Rheumatol Rep"},{"key":"3564_CR44","doi-asserted-by":"publisher","first-page":"6714","DOI":"10.3390\/jcm11226714","volume":"11","author":"JI Shin","year":"2022","unstructured":"Shin JI, Lee KH, Park S, Yang JW, Kim HJ, Song K, et al. Systemic lupus erythematosus and lung involvement: a comprehensive review. J Clin Med. 2022;11:6714. https:\/\/doi.org\/10.3390\/jcm11226714.","journal-title":"J Clin Med"},{"key":"3564_CR45","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/art.10461","volume":"46","author":"FA Houssiau","year":"2002","unstructured":"Houssiau FA, Vasconcelos C, D\u2019Cruz D, Sebastiani GD, Garrido EDR, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121\u201331. https:\/\/doi.org\/10.1002\/art.10461.","journal-title":"Arthritis Rheum"},{"key":"3564_CR46","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJM198603063141004","volume":"314","author":"HA Austin","year":"1986","unstructured":"Austin HA, Klippel JH, Balow JE, Le Riche NGH, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. N Engl J Med. 1986;314:614\u20139. https:\/\/doi.org\/10.1056\/NEJM198603063141004.","journal-title":"N Engl J Med"},{"key":"3564_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jdv.12041","volume":"28","author":"JMPA Van Den Reek","year":"2014","unstructured":"Van Den Reek JMPA, Van L\u00fcmig PPM, Janssen M, Schers HJ, Hendriks JCM, Van De Kerkhof PCM, et al. Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases. J Eur Acad Dermatol Venereol. 2014;28:27\u201333. https:\/\/doi.org\/10.1111\/jdv.12041.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3564_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/annrheumdis-2012-202099","volume":"73","author":"S Bernatsky","year":"2014","unstructured":"Bernatsky S, Ramsey-Goldman R, Joseph L, Boivin J-F, Costenbader KH, Urowitz MB, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73:138\u201342. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202099.","journal-title":"Ann Rheum Dis"},{"key":"3564_CR49","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3899\/jrheum.140863","volume":"42","author":"A Tambralli","year":"2015","unstructured":"Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42:541\u20136. https:\/\/doi.org\/10.3899\/jrheum.140863.","journal-title":"J Rheumatol"},{"key":"3564_CR50","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","volume":"33","author":"J Hogan","year":"2018","unstructured":"Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Desch\u00eanes G, et al. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol. 2018;33:111\u20136. https:\/\/doi.org\/10.1007\/s00467-017-3767-4.","journal-title":"Pediatr Nephrol"},{"key":"3564_CR51","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.2147\/DDDT.S216193","volume":"14","author":"M Guzman","year":"2020","unstructured":"Guzman M, Hui-Yuen JS. Management of pediatric systemic lupus erythematosus: focus on belimumab. Drug Des Devel Ther. 2020;14:2503\u201313. https:\/\/doi.org\/10.2147\/DDDT.S216193.","journal-title":"Drug Des Devel Ther"},{"key":"3564_CR52","doi-asserted-by":"publisher","first-page":"101962","DOI":"10.1016\/j.berh.2024.101962","volume":"38","author":"J Thuner","year":"2024","unstructured":"Thuner J, Cognard J, Belot A. How to treat monogenic SLE? Best Pract Res Clin Rheumatol. 2024;38:101962. https:\/\/doi.org\/10.1016\/j.berh.2024.101962.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"3564_CR53","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(21)00578-X.","journal-title":"Lancet"},{"key":"3564_CR54","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1:e208\u201319. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1.","journal-title":"Lancet Rheumatol"},{"key":"3564_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-024-00990-4","volume":"22","author":"I Stojkic","year":"2024","unstructured":"Stojkic I, Harper L, Coss S, Kallash M, Driest K, Lamb M, et al. CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope? Pediatr Rheumatol. 2024;22:1\u201311. https:\/\/doi.org\/10.1186\/s12969-024-00990-4.","journal-title":"Pediatr Rheumatol"},{"key":"3564_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41409-019-0430-7","volume":"54","author":"H Jessop","year":"2019","unstructured":"Jessop H, Farge D, Saccardi R, Alexander T, Rovira M, Sharrack B, et al. General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): a position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplant. 2019;54:933\u201342. https:\/\/doi.org\/10.1038\/s41409-019-0430-7.","journal-title":"Bone Marrow Transplant"},{"key":"3564_CR57","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaci.2022.08.003","volume":"150","author":"M Doglio","year":"2022","unstructured":"Doglio M, Alexander T, Del Papa N, Snowden JA, Greco R. New insights in systemic lupus erythematosus: from regulatory T cells to CAR-T-cell strategies. J Allergy Clin Immunol. 2022;150:1289\u2013301. https:\/\/doi.org\/10.1016\/j.jaci.2022.08.003.","journal-title":"J Allergy Clin Immunol"},{"key":"3564_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/pr.2011.57","volume":"71","author":"T Daikeler","year":"2012","unstructured":"Daikeler T, Tichelli A, Passweg J. Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases. Pediatr Res. 2012;71:439\u201344. https:\/\/doi.org\/10.1038\/pr.2011.57.","journal-title":"Pediatr Res"},{"key":"3564_CR59","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3389\/fimmu.2019.01570","volume":"10","author":"R Greco","year":"2019","unstructured":"Greco R, Labopin M, Badoglio M, Veys P, Furtado Silva JM, Abinun M, et al. Allogeneic HSCT for autoimmune diseases: a retrospective study from the EBMT ADWP, IEWP, and PDWP Working Parties. Front Immunol. 2019;10:1570. https:\/\/doi.org\/10.3389\/fimmu.2019.01570.","journal-title":"Front Immunol"},{"key":"3564_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.arcped.2018.12.002","volume":"26","author":"B Bader-Meunier","year":"2019","unstructured":"Bader-Meunier B, Gitiaux C, Belot A, Brochard K, Mouy R, Ponce D, et al. French expert opinion for the management of juvenile dermatomyositis. Arch P\u00e9diatrie. 2019;26:120\u20135. https:\/\/doi.org\/10.1016\/j.arcped.2018.12.002.","journal-title":"Arch P\u00e9diatrie"},{"key":"3564_CR61","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12969-022-00723-5","volume":"20","author":"K Nishi","year":"2022","unstructured":"Nishi K, Ogura M, Tamai N, Gima M, Ide K, Koinuma G, et al. Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol. 2022;20:60. https:\/\/doi.org\/10.1186\/s12969-022-00723-5.","journal-title":"Pediatr Rheumatol"},{"key":"3564_CR62","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/acr.20015","volume":"62","author":"A Ravelli","year":"2010","unstructured":"Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62:63\u201372. https:\/\/doi.org\/10.1002\/acr.20015.","journal-title":"Arthritis Care Res"},{"key":"3564_CR63","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/acr.21753","volume":"64","author":"N Martin","year":"2012","unstructured":"Martin N, Krol P, Smith S, Beard L, Pilkington CA, Davidson J, et al. Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res. 2012;64:1665\u201372. https:\/\/doi.org\/10.1002\/acr.21753.","journal-title":"Arthritis Care Res"},{"key":"3564_CR64","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/rheumatology\/keaa497","volume":"60","author":"CT Deakin","year":"2021","unstructured":"Deakin CT, Papadopoulou C, McCann LJ, Martin N, Al-Obaidi M, Compeyrot-Lacassagne S, et al. Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models. Rheumatology. 2021;60:1891\u2013901. https:\/\/doi.org\/10.1093\/rheumatology\/keaa497.","journal-title":"Rheumatology"},{"key":"3564_CR65","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12969-022-00754-y","volume":"20","author":"C Boros","year":"2022","unstructured":"Boros C, McCann L, Simou S, Cancemi D, Ambrose N, Pilkington CA, et al. Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. Pediatr Rheumatol. 2022;20:102. https:\/\/doi.org\/10.1186\/s12969-022-00754-y.","journal-title":"Pediatr Rheumatol"},{"key":"3564_CR66","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"FB Enders","year":"2017","unstructured":"Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329\u201340. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209247.","journal-title":"Ann Rheum Dis"},{"key":"3564_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Loganathan P, Koontz D, Qi Z, Reed AM, Oddis CV. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology. 2017;56:247\u201354. https:\/\/doi.org\/10.1093\/rheumatology\/kew396.","journal-title":"Rheumatology"},{"key":"3564_CR68","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12969-017-0174-0","volume":"15","author":"C Spencer","year":"2017","unstructured":"Pediatric Rheumatologist Collaborators, Spencer C, Rouster-Stevens K, Gewanter H, Syverson G, Modica R, et al. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol. 2017;15:50. https:\/\/doi.org\/10.1186\/s12969-017-0174-0.","journal-title":"Pediatr Rheumatol"},{"key":"3564_CR69","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","volume":"60","author":"T Le Voyer","year":"2021","unstructured":"Le Voyer T, Gitiaux C, Authier F-J, Bodemer C, Melki I, Quartier P, et al. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. Rheumatology. 2021;60:5801\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keab116.","journal-title":"Rheumatology"},{"key":"3564_CR70","doi-asserted-by":"publisher","first-page":"962585","DOI":"10.3389\/fped.2022.962585","volume":"10","author":"Z Wang","year":"2022","unstructured":"Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J, et al. Short-term effectiveness of baricitinib in children with refractory and\/or severe juvenile dermatomyositis. Front Pediatr. 2022;10:962585. https:\/\/doi.org\/10.3389\/fped.2022.962585.","journal-title":"Front Pediatr"},{"key":"3564_CR71","doi-asserted-by":"publisher","first-page":"103248","DOI":"10.1016\/j.jaut.2024.103248","volume":"147","author":"M Solignac","year":"2024","unstructured":"Solignac M, Cabrera N, Fouillet-Desjonqueres M, Duquesne A, Laurent A, Foray A-P, et al. JAK inhibitors in refractory juvenile rheumatic diseases: efficacy, tolerance and type-I interferon profiling, a single center retrospective study. J Autoimmun. 2024;147:103248. https:\/\/doi.org\/10.1016\/j.jaut.2024.103248.","journal-title":"J Autoimmun"},{"key":"3564_CR72","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/art.42450","volume":"75","author":"RV Curiel","year":"2023","unstructured":"Curiel RV, Nguyen W, Mamyrova G, Jones D, Ehrlich A, Brindle KA, et al. Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy. Arthritis Rheumatol. 2023;75:1229\u201337. https:\/\/doi.org\/10.1002\/art.42450.","journal-title":"Arthritis Rheumatol"},{"key":"3564_CR73","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1182\/blood-2015-06-649145","volume":"127","author":"EM Delemarre","year":"2016","unstructured":"Delemarre EM, van den Broek T, Mijnheer G, Meerding J, Wehrens EJ, Olek S, et al. Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood. 2016;127:91\u2013101. https:\/\/doi.org\/10.1182\/blood-2015-06-649145.","journal-title":"Blood"},{"key":"3564_CR74","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024\u20138. https:\/\/doi.org\/10.1073\/pnas.86.24.10024.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3564_CR75","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3564_CR76","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0548.","journal-title":"Cancer Discov"},{"key":"3564_CR77","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv. 2024;8:337\u201342. https:\/\/doi.org\/10.1182\/bloodadvances.2023011992.","journal-title":"Blood Adv"},{"key":"3564_CR78","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:16015. https:\/\/doi.org\/10.1038\/mto.2016.15.","journal-title":"Mol Ther Oncolytics"},{"key":"3564_CR79","doi-asserted-by":"publisher","first-page":"103354","DOI":"10.1016\/j.ebiom.2021.103354","volume":"67","author":"ES Atsavapranee","year":"2021","unstructured":"Atsavapranee ES, Billingsley MM, Mitchell MJ. Delivery technologies for T cell gene editing: applications in cancer immunotherapy. EBioMedicine. 2021;67:103354. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103354.","journal-title":"EBioMedicine"},{"key":"3564_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher J, Brentjens RJ, Gunset G, Rivi\u00e8re I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta \/CD28 receptor. Nat Biotechnol. 2002;20:70\u20135. https:\/\/doi.org\/10.1038\/nbt0102-70.","journal-title":"Nat Biotechnol"},{"key":"3564_CR81","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med N Y N. 2022;3:538\u201364. https:\/\/doi.org\/10.1016\/j.medj.2022.05.001.","journal-title":"Med N Y N"},{"key":"3564_CR82","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/2326-6066.CIR-15-0048","volume":"3","author":"AJ Davenport","year":"2015","unstructured":"Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, et al. CAR-T cells inflict sequential killing of multiple tumor target cells. Cancer Immunol Res. 2015;3:483\u201394. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0048.","journal-title":"Cancer Immunol Res"},{"key":"3564_CR83","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","volume":"126","author":"M Mamonkin","year":"2015","unstructured":"Mamonkin M, Rouce RH, Tashiro H, Brenner MK. A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015;126:983\u201392. https:\/\/doi.org\/10.1182\/blood-2015-02-629527.","journal-title":"Blood"},{"key":"3564_CR84","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, V\u00f6lkl S, Aigner M, Bozec A, et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of b cells in systemic lupus erythematosus. Arthritis Rheumatol. 2024;76:497\u2013504. https:\/\/doi.org\/10.1002\/art.42784.","journal-title":"Arthritis Rheumatol"},{"key":"3564_CR85","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1007\/s12015-021-10251-6","volume":"17","author":"W Zhang","year":"2021","unstructured":"Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Rev Rep. 2021;17:2120\u20133. https:\/\/doi.org\/10.1007\/s12015-021-10251-6.","journal-title":"Stem Cell Rev Rep"},{"key":"3564_CR86","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385:567\u20139. https:\/\/doi.org\/10.1056\/NEJMc2107725.","journal-title":"N Engl J Med"},{"key":"3564_CR87","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/acr2.11614","volume":"5","author":"A Boulougoura","year":"2023","unstructured":"Boulougoura A, Gendelman H, Surmachevska N, Kyttaris VC. Journal Club: Anti-CD19 chimeric antigen receptor T cell therapy for refractory systemic lupus erythematosus. ACR Open Rheumatol. 2023;5:624\u20138. https:\/\/doi.org\/10.1002\/acr2.11614.","journal-title":"ACR Open Rheumatol"},{"key":"3564_CR88","doi-asserted-by":"publisher","unstructured":"Wilhelm A, Chambers D, M\u00fcller F, Bozec A, Grieshaber-Bouyer R, Winkler T, et al. Selective CAR-T cell mediated B cell depletion suppresses interferon signature in SLE. JCI Insight. 2024. https:\/\/doi.org\/10.1172\/jci.insight.179433.","DOI":"10.1172\/jci.insight.179433"},{"key":"3564_CR89","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","volume":"128","author":"VG Bhoj","year":"2016","unstructured":"Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360\u201370. https:\/\/doi.org\/10.1182\/blood-2016-01-694356.","journal-title":"Blood"},{"key":"3564_CR90","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13075-020-02292-y","volume":"22","author":"SK Sharma","year":"2020","unstructured":"Sharma SK, Jain S, Bahl P, Potturi P, Rathi M, Naidu S, et al. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study. Arthritis Res Ther. 2020;22:189. https:\/\/doi.org\/10.1186\/s13075-020-02292-y.","journal-title":"Arthritis Res Ther"},{"key":"3564_CR91","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14:84. https:\/\/doi.org\/10.1038\/s41408-024-01048-0.","journal-title":"Blood Cancer J"},{"key":"3564_CR92","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s15010-020-01521-5","volume":"49","author":"I Los-Arcos","year":"2021","unstructured":"Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, D\u00edaz De Heredia C, Fortuny-Guasch C, et al. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49:215\u201331. https:\/\/doi.org\/10.1007\/s15010-020-01521-5.","journal-title":"Infection"},{"key":"3564_CR93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/d41586-024-01215-0","volume":"629","author":"C Willyard","year":"2024","unstructured":"Willyard C. Do cutting-edge CAR-T-cell therapies cause cancer? What the data say Nature. 2024;629:22\u20134. https:\/\/doi.org\/10.1038\/d41586-024-01215-0.","journal-title":"What the data say Nature"},{"key":"3564_CR94","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, Shi S, Bulterys PL, Liu CL, et al. Risk of second tumors and T-cell lymphoma after CAR T-Cell therapy. N Engl J Med. 2024;390:2047\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2401361.","journal-title":"N Engl J Med"},{"key":"3564_CR95","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/bloodadvances.2024013243","volume":"8","author":"AJ Lamble","year":"2024","unstructured":"Lamble AJ, Schultz LM, Nguyen K, Hsieh EM, McNerney K, Rouce RH, et al. Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024;8:3544\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2024013243.","journal-title":"Blood Adv"},{"key":"3564_CR96","doi-asserted-by":"publisher","first-page":"102361","DOI":"10.1016\/j.autrev.2019.102361","volume":"18","author":"O Omarjee","year":"2019","unstructured":"Omarjee O, Picard C, Frachette C, Moreews M, Rieux-Laucat F, Soulas-Sprauel P, et al. Monogenic lupus: dissecting heterogeneity. Autoimmun Rev. 2019;18:102361. https:\/\/doi.org\/10.1016\/j.autrev.2019.102361.","journal-title":"Autoimmun Rev"},{"key":"3564_CR97","doi-asserted-by":"publisher","first-page":"eadi9769","DOI":"10.1126\/sciimmunol.adi9769","volume":"9","author":"C Wolf","year":"2024","unstructured":"Wolf C, Lim EL, Mokhtari M, Kind B, Odainic A, Lara-Villacanas E, et al. UNC93B1 variants underlie TLR7-dependent autoimmunity. Sci Immunol. 2024;9:eadi9769. https:\/\/doi.org\/10.1126\/sciimmunol.adi9769.","journal-title":"Sci Immunol"},{"key":"3564_CR98","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/art.38008","volume":"65","author":"A Belot","year":"2013","unstructured":"Belot A, Kasher PR, Trotter EW, Foray A-P, Debaud A-L, Rice GI, et al. Protein kinase c\u03b4 deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation. Arthritis Rheum. 2013;65:2161\u201371. https:\/\/doi.org\/10.1002\/art.38008.","journal-title":"Arthritis Rheum"},{"key":"3564_CR99","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s10875-024-01660-6","volume":"44","author":"C David","year":"2024","unstructured":"David C, Badonyi M, Kechiche R, Insalaco A, Zecca M, De Benedetti F, et al. Interface gain-of-function mutations in TLR7 cause systemic and neuro-inflammatory disease. J Clin Immunol. 2024;44:60. https:\/\/doi.org\/10.1007\/s10875-024-01660-6.","journal-title":"J Clin Immunol"},{"key":"3564_CR100","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri3850","volume":"15","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Manel N. Aicardi-Gouti\u00e8res syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15:429\u201340. https:\/\/doi.org\/10.1038\/nri3850.","journal-title":"Nat Rev Immunol"},{"key":"3564_CR101","doi-asserted-by":"publisher","unstructured":"Burki T. CAR T-cell therapy for SLE in children. Lancet Rheumatol. 2024:S2665991324000985. https:\/\/doi.org\/10.1016\/S2665-9913(24)00098-5.","DOI":"10.1016\/S2665-9913(24)00098-5"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03564-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03564-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T05:37:55Z","timestamp":1746855475000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03564-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3564"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03564-1","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"31 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MJ is a consultant for Novartis. MS is a consultant for Abbvie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Fresenius Kabi, Galapagos, Innate Pharma, Nordic Pharma, Novartis, Sandoz. JA: Honoraria: Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, and MSD. Research grants: Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos, Nordic Pharma. AB is a consultant for Kabi, Roche Chugai, GlaxoSmithKline, AbbVie, Novartis, and Boehringer Ingelheim.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"102"}}